Resources from the same session
LBA48 - CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
Presenter: Glenwood Goss
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA48
Presenter: Pilar Garrido Lopez
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Slides
Webcast
Q&A
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Webcast
LBA81 - Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial
Presenter: Suresh Senan
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Abstract
Slides
Webcast
1786O - BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study
Presenter: Ewa Kalinka
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA81 and 1786MO
Presenter: Stephen Liu
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Slides
Webcast
LBA83 - PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma
Presenter: Jordi Remon Masip
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA83
Presenter: Fiona Blackhall
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Slides
Webcast
Q&A
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Webcast